16,970 Shares in United Therapeutics Corporation $UTHR Acquired by Nykredit A S

Nykredit A S purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 16,970 shares of the biotechnology company’s stock, valued at approximately $9,195,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Proficio Capital Partners LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at $438,000. BTG Pactual Asset Management US LLC purchased a new stake in United Therapeutics in the 2nd quarter worth $366,000. Headlands Technologies LLC bought a new stake in United Therapeutics during the second quarter valued at about $4,458,000. Quantitative Investment Management LLC bought a new stake in United Therapeutics during the second quarter valued at about $992,000. Finally, Two Sigma Securities LLC lifted its position in shares of United Therapeutics by 434.5% in the second quarter. Two Sigma Securities LLC now owns 2,726 shares of the biotechnology company’s stock valued at $1,477,000 after acquiring an additional 2,216 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application for Tyvaso in idiopathic pulmonary fibrosis (IPF). The application is supported by Phase 3 TETON data showing improved lung function and reduced clinical worsening. FDA review is expected to conclude in April 2027, and approval could materially expand Tyvaso’s addressable market. FDA Accepts UTHR’s sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target near $646. However, several firms have recently lowered their targets, indicating that optimism about UTHR’s pipeline and valuation is tempered by execution and growth concerns. Analyst Sentiment on United Therapeutics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, while EVP Paul Mahon sold 8,300 shares for about $4.00 million. Mahon’s sale reduced his holdings by 15.52%, and the transactions may be weighing on investor sentiment, even though the CEO’s sale was disclosed through an SEC filing and may have been prearranged. United Therapeutics Insider Selling
• Negative Sentiment: The latest quarterly results exceeded EPS expectations, but revenue of $783.3 million fell short of the $804.7 million consensus estimate and declined 1.9% year over year. The revenue weakness, combined with competition affecting pulmonary hypertension therapies, helps explain why investors remain cautious after earnings. United Therapeutics Earnings Performance

Insider Activity at United Therapeutics

In other news, EVP Paul Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total transaction of $4,000,849.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $21,774,259.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $493.46, for a total transaction of $4,687,870.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $160,099,642.78. This trade represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 404,075 shares of company stock worth $214,704,893 over the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Down 0.5%

Shares of United Therapeutics stock opened at $487.61 on Friday. United Therapeutics Corporation has a twelve month low of $375.61 and a twelve month high of $609.35. The business has a 50-day moving average price of $525.95 and a 200-day moving average price of $539.55. The firm has a market cap of $20.91 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.43 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the business earned $6.41 earnings per share. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent analyst reports. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Royal Bank Of Canada dropped their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.